1. Home
  2. ADTN vs AUTL Comparison

ADTN vs AUTL Comparison

Compare ADTN & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ADTRAN Holdings Inc.

ADTN

ADTRAN Holdings Inc.

HOLD

Current Price

$7.61

Market Cap

559.8M

ML Signal

HOLD

Logo Autolus Therapeutics plc

AUTL

Autolus Therapeutics plc

BUY

Current Price

$1.80

Market Cap

596.2M

Sector

Health Care

ML Signal

BUY

Company Overview

Basic Information
Metric
ADTN
AUTL
Founded
1985
2014
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
559.8M
596.2M
IPO Year
1996
2025

Fundamental Metrics

Financial Performance
Metric
ADTN
AUTL
Price
$7.61
$1.80
Analyst Decision
Buy
Strong Buy
Analyst Count
9
9
Target Price
★ $14.67
$8.73
AVG Volume (30 Days)
1.4M
★ 1.5M
Earning Date
11-03-2026
11-11-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 90.83
N/A
EPS
★ N/A
N/A
Revenue
★ $1,083,807,000.00
$10,120,000.00
Revenue This Year
$5.74
$98.68
Revenue Next Year
$7.88
$28.47
P/E Ratio
★ N/A
N/A
Revenue Growth
17.46
★ 496.00
52 Week Low
$6.73
$1.18
52 Week High
$19.98
$2.58

Technical Indicators

Market Signals
Indicator
ADTN
AUTL
Relative Strength Index (RSI) 53.99 38.37
Support Level $7.43 $1.37
Resistance Level $8.73 $1.92
Average True Range (ATR) 0.26 0.10
MACD 0.11 -0.01
Stochastic Oscillator 97.22 13.64

Price Performance

Historical Comparison
ADTN
AUTL

About ADTN ADTRAN Holdings Inc.

Adtran Holdings Inc is a provider of networking and communications platforms, software, and services focused on the broadband access market. It operates under two reportable segments: Network Solutions segment, which includes hardware and software products that enable a digital future that supports the company's Subscriber, Access & Aggregation, and Optical Networking Solutions; and Services & Support segment, which includes network design, implementation, maintenance and cloud-hosted services supporting the company's Subscriber, Access & Aggregation, and Optical Networking Solutions. It generates the majority of its revenue from the Network Solutions segment.

About AUTL Autolus Therapeutics plc

Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.

Share on Social Networks: